----item----
version: 1
id: {74A36F8E-6725-4480-8467-A78ABA2F680D}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/07/29/FDA Discloses FY 2016 Drug User Fee Rates
parent: {BEC3B212-EAA2-4ACE-8629-63E1A9A454B0}
name: FDA Discloses FY 2016 Drug User Fee Rates
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 6186149c-8288-4c3d-839f-95c02b2abcd2

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 41

FDA Discloses FY 2016 Drug User Fee Rates
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 41

FDA Discloses FY 2016 Drug User Fee Rates
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 3581

<p>The FDA on August 3 published the rates for fiscal year 2016 for user fees the agency intends to collect from makers of pharmaceuticals, biosimilars and generics and from firms considered pharmacy compounding outsourcing facilities.</p><p>The new fee rates take effect Oct. 1.</p><p>Under the fifth round of the <i>Prescription Drug User Fee Act</i> (PDUFA V), the base rate was $718,669,000, which has been adjusted each year after FY 2013 for inflation and workload.</p><p>The PDUFA V application fees for <a href="https://www.federalregister.gov/articles/2015/08/03/2015-18914/prescription-drug-user-fee-rates-for-fiscal-year-2016" target="_new">FY 2016</a> are:</p><p>? Requiring clinical data: $2,374,200</p><p>? Not requiring clinical data: $1,187,100</p><p>? Supplements requiring clinical data: $1,187,100</p><p>? Establishments: $585,200</p><p>? Products: $114,450</p><p>Under the <i>Generic Drug User Fee Amendments</i>, or GDUFA, the base revenue amount for FY 2016 is $299m, as set in the statute prior to the inflation adjustment. </p><p>GDUFA directs FDA to use the yearly revenue amount as a starting point to set the fee rates for each fee type.</p><p>The GDUFA fees for the abbreviated new drug applications (ANDAs), prior approval supplements to an approved (PAS), drug master files (DMFs) are increasing in FY 2016 over the corresponding fees in the current fiscal year due to a drop in the number of submissions in each of those three categories over the course of FY 2015. </p><p>The fees for all types of facilities are decreasing in FY 2016 over the corresponding fees in FY 2015 due to an increase in the number of facilities that self-identified for the next fiscal year.</p><p>For FY 2016, the <a href="https://www.federalregister.gov/articles/2015/08/03/2015-18915/generic-drug-user-fee-abbreviated-new-drug-application-prior-approval-supplement-drug-master-file" target="_new">generic drug fee rates</a> are: </p><p>?ANDA: $76,030</p><p>? PAS: $38,020</p><p>? DMF: $42,170</p><p>? Domestic active pharmaceutical ingredient (API) facility: $40,867</p><p>? Foreign API facility: $55,867</p><p>? Domestic finished dosage form (FDF) facility: $243,905</p><p>? Foreign FDF facility: $258,905</p><p>The <i>Biosimilar User Fee Act of 2012</i> (BsUFA) directs the FDA to establish, before the beginning of each fiscal year, the initial and annual biosimilar biological product development (BPD) fees, the reactivation fee and the biosimilar biological product application, establishment and product fees. </p><p>For FY 2016, the <a href="https://www.federalregister.gov/articles/2015/08/03/2015-18908/biosimilar-user-fee-rates-for-fiscal-year-2016" target="_new">BsUFA fee rates</a> are:</p><p>? Initial BPD: $237,420</p><p>? Annual BPD: $237,420</p><p>? Reactivation: $474,840</p><p>Applications:</p><p>? Requiring clinical data: $2,3747,200</p><p>? Not requiring clinical data: $1,187,100</p><p>? Supplement requiring clinical data: $1,187,100</p><p>? Establishment: $585,200</p><p>? Product: $114,450</p><p>Under the <i>Drug Quality and Security Act</i>, the FDA may collect establishment and reinspection fees from firms that elect to register as compounding outsourcing facilities.</p><p>For FY 2016, the <a href="https://www.federalregister.gov/articles/2015/08/03/2015-18916/outsourcing-facility-fee-rates-for-fiscal-year-2016" target="_new">compounding outsourcing facilities rates</a> are: </p><p>? Small business establishment fee: $5,203</p><p>? Non-small business establishment fee: $16,465</p><p>? Reinspection fee: $15,610</p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 239

<p>The FDA on August 3 published the rates for fiscal year 2016 for user fees the agency intends to collect from makers of pharmaceuticals, biosimilars and generics and from firms considered pharmacy compounding outsourcing facilities.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 41

FDA Discloses FY 2016 Drug User Fee Rates
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150729T110000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150729T110000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150729T110000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029417
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 41

FDA Discloses FY 2016 Drug User Fee Rates
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359669
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042431Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

6186149c-8288-4c3d-839f-95c02b2abcd2
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042431Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
